耐药结核病监测25年:成就、挑战与前进方向
本文回顾了世界卫生组织自1994年主持的全球抗结核药物耐药性监测项目25年来在国家、区域和全球层面评估耐药趋势的成就与挑战。COVID-19大流行使耐药结核病诊断人数较疫情前下降22%,治疗人数下降15%。弥补检测缺口需投资研发新诊断工具并推广、扩大样本运输系统及实施数据连接方案。
要点
- 全球抗结核药物耐药性监测项目由世界卫生组织自1994年主持,已运行超过25年。
- COVID-19大流行使耐药结核病诊断人数较疫情前下降22%,治疗人数下降15%。
核心结论
- 耐药结核病仍然是公共卫生危机,COVID-19大流行逆转了提供基本结核病服务和减轻疾病负担方面多年的进展。
研究设计与样本
- 本文为Personal View,介绍由世界卫生组织自1994年主持的全球抗结核药物耐药性监测项目这一 oldest and largest 全球抗微生物药物耐药性监测系统的成就、挑战和前进方向。
主要发现
- 由抗微生物药物耐药性导致的死亡中约四分之一由利福平耐药结核病引起。
- COVID-19大流行以来,被诊断患有耐药结核病的人数较疫情前下降22%,接受耐药结核病治疗的患者人数下降15%。
临床怎么用
- 弥补耐药结核病检测缺口需要投资研发和推广新诊断工具、扩大样本运输系统以及实施数据连接解决方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tuberculosis is second only to COVID-19 as a cause of death from a single infectious agent. In 2020, almost 10 million people were estimated to have developed tuberculosis and it caused 1·5 million deaths. Around a quarter of deaths caused by antimicrobial resistance are due to rifampicin-resistant tuberculosis. Antimicrobial resistance surveillance systems for many bacterial pathogens are still in the early stages of implementation in many countries, and do not yet allow for the estimation of disease burden at the national level. In this Personal View, we present the achievements, challenges, and way forward for the oldest and largest global antimicrobial resistance surveillance system. Hosted by WHO since 1994, the Global Project on Anti-Tuberculosis Drug Resistance Surveillance has served as a platform for the evaluation of the trends in anti-tuberculosis drug resistance for over 25 years at country, regional, and global levels. With an estimated 465 000 incident cases of multidrug-resistant and rifampicin-resistant tuberculosis in 2019, drug-resistant tuberculosis remains a public health crisis. The COVID-19 pandemic has reversed years of progress in providing essential tuberculosis services and reducing disease burden. The number of people diagnosed with drug-resistant tuberculosis has dropped by 22% since before the pandemic, and the number of patients provided with treatment for drug-resistant tuberculosis has dropped by 15%. Now more than ever, closing gaps in the detection of drug-resistant tuberculosis requires investment in research and development of new diagnostic tools and their rollout, expansion of sample transport systems, and the implementation of data connectivity solutions.
引用
- Dean AS, Tosas Auguet O, Glaziou P, et al. 25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward. Lancet Infect Dis. 2022. PMID: 35248168. doi:10.1016/S1473-3099(21)00808-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。